Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Jiudian Pharmaceutical: Fumaric Acid Imesustin Extended-Release Capsule Drug Registration Certificate
Jiudian Pharmaceutical announced that it has recently received the drug registration certificate for Fumaric Acid Emestine Extended-Release Capsules issued by the National Medical Products Administration. The Fumaric Acid Emestine Extended-Release Capsules are indicated for the treatment of allergic rhinitis and urticaria. They were first approved for marketing in Japan in 1993, and currently are sold domestically and internationally in forms including extended-release capsules, eye drops, and patches. According to Minet Data, in 2022, 2023, and 2024, the sales of Fumaric Acid Emestine Extended-Release Capsules in China’s three major terminal markets and six major segments were 84.19 million yuan, 143 million yuan, and 176 million yuan, respectively.